Prospectus Supplement                         Filed Pursuant to Rule 424(b)(3)
(to Prospectus dated October 5, 2004)         Registration No. 333-118922



                         ADVANCED MEDICAL OPTICS, INC.

                                 $350,000,000

             2.50% Convertible Senior Subordinated Notes due 2024
                                      and
         Shares of Common Stock Issuable Upon Conversion of the Notes



         This prospectus supplement supplements the prospectus dated October
5, 2004, as supplemented by prospectus supplements dated October 19, 2004,
November 4, 2004, November 10, 2004, December 13, 2004, January 11, 2005,
February 7, 2005, March 18, 2005, April 20, 2005 and May 24, 2005 relating to
the resale by certain of our securityholders of up to $350,000,000 aggregate
principal amount at maturity of our 2.50% Convertible Senior Subordinated
Notes due 2024 and the shares of our common stock issuable upon conversion of
the notes. You should read this prospectus supplement in conjunction with the
prospectus. This prospectus supplement is qualified by reference to the
prospectus, except to the extent that the information in this prospectus
supplement supersedes the information contained in the prospectus.

         Effective December 15, 2004, as permitted by the indenture governing
the notes, we made an irrevocable election to satisfy in cash our conversion
obligation with respect to the principal amount of any notes converted after
December 15, 2004, with any remaining amount of the conversion obligation to
be satisfied in shares of common stock, in each case, calculated as set forth
in the indenture.

         The information appearing under the heading "Selling Securityholders"
in the prospectus is hereby amended by the addition or substitution, as
applicable, of the following:




                                            Aggregate      Percentage      Number of
                                            Principal      of Aggregate    Shares of     Percentage
                                             Amount        Principal         Common       of Common
                                            of Notes        Amount           Stock          Stock
                                            That May       of Notes        That May Be   Outstanding
Name of Selling Securityholder              Be Sold       Outstanding       Sold(1)          (1) 
----------------------------------------------------------------------------------------------------
                                                                              
McMahan Securities Co., L.P.(2)......       250,000             *            (1)           (1)

--------------
*        Represents less than 0.1%

(1)      As a result of our irrevocable election to satisfy in cash our
         conversion obligation with respect to the principal amount of any
         notes converted after December 15, 2004, on conversion, each holder
         will receive (A) a cash amount equal to the aggregate principal
         amount of the notes to be converted, and (B) a number of shares of
         common stock equal to (i) the aggregate principal amount of notes to
         be converted divided by 1,000 and multiplied by (ii)(a) the
         conversion rate then in effect minus (b) $1,000 divided by the
         applicable stock price (as defined in the prospectus and the
         indenture). The initial conversion rate of the notes is 19.9045
         shares of common stock per $1,000 principal amount at maturity of the
         notes, subject to adjustment as described in the prospectus and the
         indenture.

(2)      Selling securityholder has identified itself as a broker-dealer. Such
         selling securityholder has informed us that: (1) such selling
         securityholder purchased its notes in the ordinary course of
         business, and (2) at the time the notes were purchased, the selling
         securityholder had no agreements or understandings, directly or
         indirectly, with any person to distribute the notes.



         Investing in the notes and our common stock issuable upon conversion
of the notes involves risks that are described in the "Risk Factors" section
of the accompanying prospectus beginning on page 13.

                                _____________

         Neither the Securities and Exchange Commission nor any state
securities commission has approved or disapproved of these securities or
determined if this prospectus supplement or the accompanying prospectus is
truthful or complete. Any representation to the contrary is a criminal
offense.

                                _____________

            The date of this prospectus supplement is July 28, 2005